Associate Professor in Internal Medicine, Dept. Medicine, University of Padova, Italy.
International PhD Degree in 'Arterial Hypertension and Vascular Biology'.
Field of interest: Clinical and translational research in high blood pressure and cardiovascular diseases.
Dr Mirela Sedic (born Bauman) is Principal Scientist at the Institute for Anthropological Research Zagreb. She has authored over 50 scientific publications in peer-reviewed journals including high-impact journals such as BBA Molecular Basis of Disease, Molecular Cancer, The Journal of Pathology, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Cancer Treatment Reviews.
She was the co-PI of international collaborative project with Functional Genomics Center Zurich in Switzerland (PRIME-XS-0000184 Proteomic profiling of retinal proteins from rat model of age-related macular degeneration 2012-2014) and the PI of the University of Rijeka grant “Screening and biological evaluation of acid ceramidase and sphingosine kinase inhibitors as a new class of anti-tumour agents” (2014 – 2017). She is currently the PI of the project funded by the Croatian Science Foundation “Dissecting the mechanisms of therapy resistance in BRAF-mutant colon cancer using an integrated –omics approach” (2019 – 2023) and the PI of the University of Rijeka research grant “Molecular features associated with BRAFV600E-mutated versus wild type BRAF colorectal cancer” (2019-2022). She is also the PI of the project No. 3238 - EPIC-XS 012: “Proteomic analysis of acquired resistance to vemurafenib in BRAF V600E–mutant colon cancer cells” (2019 - 2022) in collaboration with the Functional Genomics Center Zurich in Switzerland.
Dr. Yuan Shang works on Alzheimer's Disease (AD) at the University of Arizona. He combines any potential methods and data to search potential therapeutic opportunities for AD. He is an expert on omics data analysis, multi-omics integrations, network-based pattern recognition, and machine learning-based biomarker discoveries.
Gaurav Sharma is a biomedical researcher with expertise in intermediary metabolism and metabolic imaging. His long-term research interests are the development of magnetic resonance spectroscopy/imaging (MRS/I) techniques for the noninvasive investigation of metabolic processes under both normal and pathologic conditions that can be applied in preclinical and clinical settings. Gaurav's current research focus is mainly in two areas: first, development of novel methods for non-invasive assessment of metabolism and second, understanding the intermediary metabolism in biological systems. In particular, his research involved the use of dynamic nuclear polarization to increase the MR signal of metabolically active, 13C-labeled probes for accessing metabolism in isolated perfused organs and in vivo metabolic imaging, and 13C-NMR isotopomer analysis for assessing in vivo metabolic flux.
Dr. Himangshu Sonowal is Assistant Project Scientist within the Moores Cancer Center, Division of Hematology, Department of Medicine at the University of California, San Diego.
His research expertise includes Cell and Molecular Biology, Biochemical Pharmacology, Cancer, Vascular Biology, Diabetes and Inflammation.
Nicholas Syn, MBBS, is a researcher at Yong Loo Lin School of Medicine, National University of Singapore. His research interests are in general surgery, transplant surgery, and translational oncology. He has published over 109 PubMed-indexed articles in these areas, and has a H-index of 19 (updated as of 16th Apr, 2021).
I have been working on the molecular mechanisms of cancer progression and metastasis for the last ten years, identifying signaling pathways that promote cancer progression using various in vitro and in vivo models. During this time, I have published 30 articles with more than 2000 citations, and 12 papers have been cited as being in the top 10% of the field. They have mostly appeared in high-impact journals such as Sci. Adv., Nat. Comm., J. Exp. Med., Clinical Can. Res., Oncogene, Cancer Res., Cancer Letters. My research is primarily concerned with mechanistic and translational studies of tumor-initiating cells, the microenvironment, and non-coding RNAs in the context of cancer progression and metastasis. My long-term research goal is to conduct basic and translational research to elucidate the underlying mechanism(s) driving cancer metastasis and identify therapeutic targets, especially for highly aggressive metastatic cancers. In addition, I also serve on the editorial boards of three cancer-related journals. Before joining the department of Cancer Biology at Wake Forest University School of Medicine, I was a senior research officer (SRO) at the Delhi State Cancer Institute, India (Govt. of India).
I am or have been...
1. A self-motivated, goal-oriented cellular/molecular biologist with over 7 years of experience in oncology.
2. Substantial experience in designing and executing well-controlled in vitro and in vivo assays for preclinical drug discovery, synthetic lethal screening, biomarker identification, target validation, immunogenicity, and toxicity assessment
3. Capable of investigating signaling pathways with a variety of molecular and genetic tools
4. Enthusiastic team worker and expert in forming strategic collaborations
Dr. Shibiao Wan is currently an Assistant Professor in the Department of Genetics, Cell Biology and Anatomy at University of Nebraska Medical Center (UNMC). He is also the Assistant Director for Bioinformatics and Systems Biology Core at UNMC.
With more than 14 years of experience in machine learning, bioinformatics, and computational biology, Dr. Wan has published >50 articles in top-tiered journals such as Genome Research, Nature Communications, Science Advances, Circulation Research, Briefings in Bioinformatics, and Bioinformatics. Dr. Wan is the Editor-in-Chief for Current Proteomics, and an Editorial Board Member for a series of prestigious journals such as Briefings in Functional Genomics, Heliyon, BMC Bioinformatics, International Journal of Microbiology, PeerJ Computer Science, BioMed Research International, and Computational and Mathematical Methods, and a guest associate editor for multiple high-impact journals including Frontiers in Immunology, Frontiers in Cell and Developmental Biology, Frontiers in Pharmacology, Biology, Frontiers in Genetics, and Genes.
Dr Wan is a TPC member for >20 machine learning related international conferences including IEEE ICTAI. Dr. Wan is also a reviewer for >50 prestigious journals including Nature Computational Science, Nucleic Acids Research, Cancer Research, Genome Medicine, and Briefings in Bioinformatics. He is a recipient of the global peer review awards (top 1%) in “Cross-Field” and “Biology and Biochemistry” in 2019 awarded by Clarivate. Dr. Wan is an Outstanding Young Alumni Awardee in 2022 and the recipient for the FIRST Award of Nebraska EPSCoR Program in 2023. Dr. Wan is a member of AACR, ISCB and ACM and an IEEE Senior Member.
Senior Lecturer in Pharmacology, University of Reading. British Neuroscience Association Local Group Representative. British Pharmacological Society (Member). UK Epilepsy Research Network (Interventions & Therapies CWG). Pharmacist (GPhC registered).
Investigating unmet clinical need in epilepsy with a specific focus on cannabinoid pharmacology using preclinical animal models and electrophysiological techniques supported by convention molecular and biochemical approaches.
Katrine Whiteson uses metagenomics, metabolomics, microbiology and ecological statistics to answer questions about how microbes and viruses affect human health. She studied Biochemistry at UC Berkeley (BA, 2000) and University of Chicago (PhD, 2007). During her PhD, Dr. Whiteson focused on the active site chemistry and DNA binding specificity of a site-specific recombinase from the class of proteins that enable the spread of antibiotic resistance genes. In 2008, she began a new job at the University of Geneva Hospitals with Dr. Jacques Schrenzel and Dr. Patrice Francois. This was an exciting era, just at the start of the Human Microbiome Project, for asking basic unanswered questions about the microbes and viruses inhabiting various niches of the human body. Dr. Whiteson focused on the oral microbial communities of healthy Europeans, and malnourished kids in Niger who develop a devastating facial gangrene known as noma. In 2011 she moved to Forest Rohwer’s lab at San Diego State, where she undertook breath and sputum metabolite analysis to better understand the activity of CF patient microbial communities from Dr. Doug Conrad’s Adult CF clinic at UCSD. Combining information about the genetic potential of a microbial community through DNA sequencing with the activity of the community by metabolite profiling is a powerful approach that Dr. Whiteson hopes to employ in future projects as she begins her own lab at University of California Irvine in Fall 2014.
Albert H.C. Wong is a neuroscientist and psychiatrist at the Centre for Addiction and Mental Health, and a Professor at the University of Toronto. He attended medical school at the University of Toronto, where he also completed specialty training in psychiatry and a PhD in neurobiology. Dr. Wong’s lab uses animal models and clinical studies to investigate genetic, epigenetic and developmental mechanisms of psychiatric disease. His areas of clinical expertise are in schizophrenia and brain stimulation.
Hao Wu is a patent scientist in an oncology-focused biotechnology company, Exelixis, Inc. She obtained her Ph.D. in molecular biology from Rowan University (previously known as the University of Medicine and Dentistry of New Jersey (UMDNJ) – Stratford Campus). With hands-on knowledge in various aspects of biology, including molecular biology, cell biology, biochemistry, immunology, neuroscience, oncology, Hao has worked on inventions spanning a broad range of technologies, for example, biologics, antibodies, biomarkers, diagnostics, cell therapy, gene therapy, and sequencing.